Paper Details

  1. Home
  2. Paper Details

A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination.

Author: BaugherGary, CannonKevin, ElderCharles, GruberWilliam C, JansenKathrin U, PengYahong, ScottDaniel A, ScullyIngrid L, WatsonWendy, YoungMariano

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A 20-valent pneumococcal conjugate vaccine (PCV20) was developed to expand protection against pneumococcal disease. This study evaluated the safety and immunogenicity of PCV20 in adults 65 years and older who had previously received pneumococcal vaccines. The study aimed to assess the vaccine's effectiveness in providing additional protection against serotypes not covered by previous vaccines and to evaluate its safety profile in this population.
Paper Details　
Original Abstract of the Article :
A 20-valent pneumococcal conjugate vaccine, PCV20, was developed to expand protection against vaccine-preventable pneumococcal disease. PCV20 contains the components of the 13-valent pneumococcal conjugate vaccine, PCV13, and includes capsular polysaccharide conjugates for 7 additional serotypes. Th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.vaccine.2021.10.032

データ提供：米国国立医学図書館（NLM）

PCV20: A New Pneumococcal Conjugate Vaccine for Adults

The development of pneumococcal vaccines has been a major advancement in preventing pneumococcal disease. This study investigates the safety and immunogenicity of PCV20, a newly developed 20-valent pneumococcal conjugate vaccine, in adults aged 65 years and older with prior pneumococcal vaccination.

PCV20 Safety and Immunogenicity

The study demonstrated that PCV20 was safe and immunogenic in adults with prior pneumococcal vaccination. PCV20 provides broader protection against pneumococcal disease by including capsular polysaccharide conjugates for 7 additional serotypes compared to the 13-valent pneumococcal conjugate vaccine (PCV13). The findings suggest that PCV20 may be a valuable tool for expanding protection against pneumococcal disease in adults who have already received previous pneumococcal vaccines.

Enhanced Protection Against Pneumococcal Disease

This research provides important insights into the potential of PCV20 to enhance protection against pneumococcal disease in adults with prior vaccination. The study suggests that PCV20 could play a significant role in preventing pneumococcal infections in this vulnerable population. Further research is needed to evaluate the long-term effectiveness and impact of PCV20 on public health.

Dr.Camel's Conclusion

Imagine a desert oasis, where travelers gather to share knowledge and resources. Just as a caravan leader safeguards their group from potential threats, researchers are working tirelessly to develop vaccines that protect us from harmful diseases. This research, like a refreshing wellspring in the desert, offers a new tool for preventing pneumococcal disease in older adults. PCV20, a newly developed vaccine, holds promise for expanding protection and creating a safer future for all.

Date :
  1. Date Completed 2022-01-26
  2. Date Revised 2022-01-26
Further Info :

Pubmed ID

34839993

DOI: Digital Object Identifier

10.1016/j.vaccine.2021.10.032

Related Literature

Article Analysis
・Effects of pneumococcal polysaccharide vaccine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.